Inspire Medical Systems, INC 8-K filings

Inspire Medical Systems reported Q2 2026 results, with revenue down 7.6% year-over-year to $200.6 million, but raised its full-year 2026 revenue outlook and announced a strategic growth plan to generate $30 million for new initiatives.

Inspire Medical Systems, Inc. announced the immediate appointment of Michael H. Carrel to its Board of Directors, effective July 20, 2026.

Inspire Medical Systems announced the retirement of Board member Casey M. Tansey, effective July 30, 2026, after over eighteen years of service.

Inspire Medical Systems provided a comprehensive update on coding, clinical outcomes, and cardiovascular health benefits for its Inspire V therapy at the 2026 Wells Fargo MedTech Innovation Spotlight.

Inspire Medical Systems stockholders approved amendments to the incentive award plan and a declassification of the board at the April 30, 2026 annual meeting.

Inspire Medical Systems reported Q1 2026 results with a modest 1.6% revenue increase to $204.6 million, impacted by coding and reimbursement uncertainty, while revising full-year guidance downwards.

Inspire Medical Systems announced robust financial results for Q4 and full year 2025, driven by the successful Inspire V system launch, despite facing reimbursement coding challenges for 2026.

Inspire Medical Systems announced preliminary strong Q4 and full-year 2025 revenue results, provided initial 2026 guidance, and appointed Matt Osberg as its new Executive Vice President and Chief Financial Officer.

Inspire Medical Systems anticipates a significant income tax benefit of $90 million to $100 million in Q4 2025, projected to increase diluted earnings per share by $3.00 to $3.30 for the fiscal year.

Inspire Medical Systems reported strong third-quarter 2025 financial results, with revenue up 10% and a significant increase in full-year diluted net income per share guidance, driven by the successful Inspire V system transition.

Inspire Medical Systems, Inc. announced positive clinical outcomes for its new Inspire V system, demonstrating superior efficacy, improved safety, and reduced surgical times for obstructive sleep apnea patients.

Inspire Medical Systems announces CFO Richard J. Buchholz will step down by year-end 2025, transitioning to an advisory role, while reaffirming full-year 2025 financial guidance.

Inspire Medical Systems' Board of Directors has authorized a share repurchase program of up to $200 million of its common stock.

Inspire Medical Systems reported mixed second-quarter 2025 financial results, including a net loss and lowered full-year guidance, alongside the announcement of a key executive's retirement.

Inspire Medical Systems, Inc. presented its latest advancements, including the new Inspire V system for obstructive sleep apnea, and strategic priorities at the Wells Fargo 2025 MedTech Innovation Spotlight.

Inspire Medical Systems successfully held its annual meeting of stockholders on May 1, 2025, electing directors and ratifying the appointment of Ernst & Young LLP as its independent auditor.

Inspire Medical Systems announces a 23% year-over-year revenue increase and earnings per share of $0.10 for the first quarter of 2025, while maintaining its full-year revenue guidance and raising its EPS guidance.

Inspire Medical Systems announces a 25% year-over-year revenue increase and a 135% earnings per share growth for the fourth quarter of 2024, along with reaffirming its full year 2025 revenue guidance.

Inspire Medical Systems reports a 25% year-over-year revenue increase for Q4 2024 and provides initial 2025 revenue guidance of $940 million to $955 million.

Inspire Medical Systems has entered into an agreement with Goldman Sachs to repurchase $75 million of its common stock through an accelerated share repurchase program.

Inspire Medical Systems announced a 33% year-over-year revenue increase and earnings per share of $0.60 for the third quarter of 2024, leading to an increased full-year outlook.

Inspire Medical Systems reported a 30% year-over-year revenue increase in Q2 2024, raised its full-year guidance, and authorized a $150 million share repurchase program.

Inspire Medical Systems has announced FDA approval for its Inspire V therapy system, which includes a next-generation neurostimulator and associated Bluetooth devices.

Inspire Medical Systems reported preliminary unaudited second-quarter revenue of $195.9 million, a 30% increase year-over-year, and raised its full-year 2024 revenue guidance to $788-$798 million.

Inspire Medical Systems' Chief Operating Officer, Philip J. Ebeling, has resigned effective August 9, 2024, to become CEO of a private medical device company.

Inspire Medical Systems held its annual meeting on May 2, 2024, electing three Class III directors and ratifying Ernst & Young LLP as its independent auditor.

Inspire Medical Systems announced a 28% year-over-year revenue increase for the first quarter of 2024 and raised its full-year revenue guidance, now expecting to be profitable for the full year.

Inspire Medical Systems announced a 40% year-over-year revenue increase for the fourth quarter of 2023, achieving their first quarter with operating income and reaffirming their 2024 revenue guidance.

Inspire Medical Systems has announced that CEO Timothy P. Herbert will assume the additional role of Board Chair, succeeding Marilyn Carlson Nelson, who is retiring.

Inspire Medical Systems announced the retirement of Dr. Jerry C. Griffin from its Board of Directors after sixteen years of service, effective at the conclusion of the 2024 Annual Meeting of Stockholders.